Netupitant / Palonosetron -- Benefit Assessment According to §35a Social Code Book V

Netupitant / Palonosetron -- Benefit Assessment According to §35a Social Code Book V

Book. 2015 11 12

Authors: Institute for Quality and Efficiency in Health Care

Abstract
Background In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug netupitant / palonosetron. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as "the company"). The dossier was sent to IQWiG on 16 July 2015. Research question The aim of this report was to assess the added benefit of netupitant / palonosetron in adult patients for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy or with highly emetogenic cisplatin-based cancer chemotherapy in comparison with the appropriate comparator therapy (ACT). From the options specified by the G-BA, the company chose palonosetron + dexamethasone as ACT for research question A, and aprepitant + palonosetron + dexamethasone as ACT for research question B. The present assessment was conducted in comparison with the G-BA's ACT. The assessment was conducted based on patient-relevant outcomes and on the data provided by the company in the dossier.

PMID: 29144698

http://ift.tt/2irddCe